| First Author | Medler TR | Year | 2018 |
| Journal | Cancer Cell | Volume | 34 |
| Issue | 4 | Pages | 561-578.e6 |
| PubMed ID | 30300579 | Mgi Jnum | J:266018 |
| Mgi Id | MGI:6202201 | Doi | 10.1016/j.ccell.2018.09.003 |
| Citation | Medler TR, et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34(4):561-578.e6 |
| abstractText | Complement is a critical component of humoral immunity implicated in cancer development; however, its biological contributions to tumorigenesis remain poorly understood. Using the K14-HPV16 transgenic mouse model of squamous carcinogenesis, we report that urokinase (uPA)(+) macrophages regulate C3-independent release of C5a during premalignant progression, which in turn regulates protumorigenic properties of C5aR1(+) mast cells and macrophages, including suppression of CD8(+) T cell cytotoxicity. Therapeutic inhibition of C5aR1 via the peptide antagonist PMX-53 improved efficacy of paclitaxel chemotherapy associated with increased presence and cytotoxic properties of CXCR3(+) effector memory CD8(+) T cells in carcinomas, dependent on both macrophage transcriptional programming and IFNgamma. Together, these data identify C5aR1-dependent signaling as an important immunomodulatory program in neoplastic tissue tractable for combinatorial cancer immunotherapy. |
